RaQualia PharmaTSE:4579 -2.70%57 Current Ratio is 6.16 as of Mar. 2026, which is 46% below its 10-year median of 11.31. GuruFocus rates TSE:4579 with a GF Score™ of 57/100 and a GF Value™ of 円961.31 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,408 Biotechnology companies, RaQualia Pharma ranks better than 64.35% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. RaQualia Pharma's current ratio for the quarter that ended in Mar. 2026 was 6.16.
RaQualia Pharma has a current ratio of 6.16. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for RaQualia Pharma's Current Ratio or its related term are showing as below:
TSE:4579'
s Current Ratio Range Over the Past 10 Years
Min: 3.66 Med: 11.31 Max: 22.33
Current: 6.16
During the past 13 years, RaQualia Pharma's highest Current Ratio was 22.33. The lowest was 3.66. And the median was 11.31.
TSE:4579's Current Ratio is ranked better than 64.35% of 1408
companies
in the Biotechnology industry
Industry Median: 3.9
vs TSE:4579: 6.16
RaQualia Pharma (TSE:4579) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
RaQualia Pharma Current Ratio Related Terms
RaQualia Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, RaQualia Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Current Ratio of 6.16 as of Mar. 2026. This is 46% below median its historical median of 11.31. Over the past decade, RaQualia Pharma's Current Ratio has ranged from 3.66 to 22.33. According to the industry distribution chart, RaQualia Pharma ranks #502 out of 1408 companies in the Biotechnology industry, placing it in the top 35.7%.
Is RaQualia Pharma's Current Ratio too high?
RaQualia Pharma's current Current Ratio of 6.16 is 46% below median its 10-year median of 11.31. Over the past 10 years, this metric has ranged from a low of 3.66 to a high of 22.33. The Biotechnology industry median Current Ratio is 3.90. RaQualia Pharma's value of 6.16 is 57.9% above this industry median. Based on the distribution chart, RaQualia Pharma ranks #502 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #502 out of 1408 companies for Current Ratio. This puts RaQualia Pharma in the upper half of its industry. The industry median Current Ratio is 3.90. RaQualia Pharma's value of 6.16 is 57.9% above this benchmark. Historically, RaQualia Pharma's own Current Ratio has ranged from 3.66 to 22.33 over the past decade. While the company's 10-year median is 11.31 vs. the industry median of 3.90, RaQualia Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaQualia Pharma's current Current Ratio of 6.16 is 57.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current Current Ratio is 6.16, which is 46% below median its own 10-year median of 11.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current Current Ratio is 6.16, which is 46% below median its 10-year median of 11.31 and 57.9% above the Biotechnology industry median of 3.90. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Current Ratio is 6.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31.
GuruFocus considers RaQualia Pharma to be Significantly Undervalued.
Key valuation signals for TSE:4579:
Current Ratio: 6.16 (46% below median its 10-year median of 11.31)
GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
Industry Position: 57.9% above the Biotechnology median (#502 of 1408)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score
Get the complete analysis for TSE:4579
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
